|
Post by mango on Jan 30, 2020 17:05:15 GMT -5
The conversation of an Afrezza generic and ripping off Technosphere was discussed earlier this week. I noticed that some people here are not well informed on MannKind’s IP patent protection dates and expirations. We’re well protected, and continue to put out continuations and new patents ‘round the clock.
|
|
|
Post by peppy on Jan 30, 2020 17:10:49 GMT -5
mango do you have the MNKD patents link? if you do will you put it up?
|
|
|
Post by mango on Jan 30, 2020 17:12:17 GMT -5
|
|
|
Post by peppy on Jan 30, 2020 17:46:31 GMT -5
|
|
|
Post by mango on Jan 30, 2020 17:49:36 GMT -5
kowtow
|
|
|
Post by peppy on Jan 30, 2020 17:53:46 GMT -5
11. 2338506 COMBINATIONS OF TUMOR-ASSOCIATED ANTIGENS FOR THE TREATMENT OF VARIOUS TYPES OF CANCERS plenty of immunology and cancer/tumor. It always amazes me.
|
|
|
Post by brotherm1 on Jan 30, 2020 19:04:06 GMT -5
Thanks Mango. I too was recently wondering when Afrezza’s patent would expire. I believe a drug patent is good for 20 years? So the pics you posted above would indicate Afrezza was patented in 2014? I’m aware companies often change formulations to extend patents on their current products, but is the original Afrezza patent good until 2034 ? In other words, the original Afrezza formulation was not patented until 2014?
|
|
|
Post by letitride on Jan 30, 2020 19:10:21 GMT -5
Long live the Patents. Lets Go!
|
|
|
Post by ktim on Jan 30, 2020 19:49:37 GMT -5
11. 2338506 COMBINATIONS OF TUMOR-ASSOCIATED ANTIGENS FOR THE TREATMENT OF VARIOUS TYPES OF CANCERS plenty of immunology and cancer/tumor. It always amazes me. They had a pretty impressive oncology division, but it was shut down and I believe all that IP, including the patent you reference, were licensed out. I've forgotten if MNKD would get royalties but I don't think there has been any news about progress commercializing those technologies.
|
|
|
Post by ktim on Jan 30, 2020 19:52:14 GMT -5
Thanks Mango. I too was recently wondering when Afrezza’s patent would expire. I believe a drug patent is good for 20 years? So the pics you posted above would indicate Afrezza was patented in 2014? I’m aware companies often change formulations to extend patents on their current products, but is the original Afrezza patent good until 2034 ? In other words, the original Afrezza formulation was not patented until 2014? There are MANY patents that apply to Afrezza. The very earliest ones I'm sure would expire before 2034, but it wouldn't matter as long as the longer dated ones are reasonably strong.
|
|
|
Post by falconquest on Jan 30, 2020 20:06:32 GMT -5
Long live the Patents. Lets Go! Didn't they like win a bunch of Superbowls or something?
|
|
|
Post by letitride on Jan 30, 2020 20:10:29 GMT -5
Next ones going to be for Best Insulin.
|
|
|
Post by brotherm1 on Jan 30, 2020 20:16:48 GMT -5
So theoretically, someone could conceivably copy Afrezza’s earliest patent before the latest patent could be legally copied? And although the formulation of the earlier patent might not be as effective as the most recently patented Afrezza formulation, it could be legally copied and sold? Perhaps sold for a lesser cost than the most recent, but nonetheless copied and sold? Am I correct?
|
|
|
Post by brotherm1 on Jan 30, 2020 20:20:48 GMT -5
Next ones going to be for Best Insulin. Do you feel it’s necessary to frequently interject your cheer leading in the middle of conversations?
|
|
|
Post by ktim on Jan 30, 2020 20:42:26 GMT -5
So theoretically, someone could conceivably copy Afrezza’s earliest patent before the latest patent could be legally copied? And although the formulation of the earlier patent might not be as effective as the most recently patented Afrezza formulation, it could be legally copied and sold? Perhaps sold for a lesser cost than the most recent, but nonetheless copied and sold? Am I correct? The earliest patents probably are solely about TS. There could even be patents about having TS insulin that would still not produce a usable product of any kind without some later patent, and all manner of in betweens. Just making something up... let's imagine after perfecting TS they first tried loading insulin and did so with hexamers. There might still be parts of that patent relevant, but if a later one had to do with loading monomers then a competitor might plausibly be able to do something with hexamer TS before monomer, and yet (I believe) the pk/pd benefits of Afrezza would be lost (which I guess would be your case)... but that would also require full blown clinical trials since it obviously isn't biosimilar to Afrezza and no company is likely to spend a billion to try to try to undercut Afrezza with a sub par copy cat. I really think falling off patent isn't something investors should be worrying about. But the questions you are posing would really require a very deep dive into their patent portfolio, and the first part of that would be looking at what standard a competitor would need to meet at the FDA. Perhaps some expert here (Matt?) could explain the relevance of Orange Book listed patents and what standard (generic vs biosimilar) would be applied and what relevance the inhaler device patents would have. But I'd say... Don't worry about it.
|
|